SRRK - Scholar Rock Holding Corp Volatility & Greeks
This article provides a detailed financial overview of Scholar Rock Holding Corp (SRRK), including its volatility, key financial metrics, stock performance, and analyst recommendations. It highlights the company's market capitalization, income, sales, and various ratios, alongside insider and institutional ownership data.
SRRK (NASDAQ: SRRK) files Rule 144 notice to sell 5,446 shares via J.P. Morgan
Scholar Rock Holding Corp (SRRK) has filed a Rule 144 notice indicating an intention to sell 5,446 common shares through J.P. Morgan Securities LLC. These shares are related to RSU settlements scheduled for February 15, 2026 (261 shares), March 15, 2026 (745 shares), and June 15, 2026 (4,440 shares). The filing acts as a disclosure of planned sales under resale exemptions, rather than a confirmation of completed transactions.
Form 144 Scholar Rock Holding Corp. For: 1 July By Investing.com
This article announces the filing of Form 144 for Scholar Rock Holding Corp. on July 1st, as reported by Investing.com. The content itself is very brief and primarily serves as a placeholder for the news of this specific financial filing.
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from Analysts
Scholar Rock Holding Corporation (NASDAQ:SRRK) has received a consensus "Buy" recommendation from 17 analysts, with an average 1-year price target of $56.00. While some recent analyst updates included price target increases, Weiss Ratings reiterated a "sell" rating. The stock traded near its 52-week high after reporting a quarterly loss of ($0.83) per share, and insider selling occurred due to tax withholdings on equity awards.
Scholar Rock Holding Corp. Actuals & Estimates (NASDAQ:SRRK)
This article provides an in-depth financial overview of Scholar Rock Holding Corporation (NASDAQ:SRRK), including its current stock price, historical performance, analyst forecasts, and key financial metrics. It covers revenue, earnings, market capitalization, and volatility, offering insights for potential investors. The company's next earnings report is scheduled for August 12, 2026.
Price to sales forward of Scholar Rock Holding Corp. – LSX:A2JMQW
This article provides access to the forward price-to-sales ratio for Scholar Rock Holding Corp. (A2JMQW) on the Lang & Schwarz Exchange, available through TradingView. It indicates that the market is currently closed with no active trades. The content highlights the financial overview of the company for investors.
Enterprise value to EBITDA forward of Scholar Rock Holding Corp. – LSX:A2JMQW
This page provides financial data for Scholar Rock Holding Corp. (LSX:A2JMQW) on TradingView, specifically focusing on its Enterprise Value to EBITDA forward metric. The content highlights that market data is provided by ICE Data Services and FactSet, with SEC filings from Quartr. The page appears to be part of a larger financial information platform, offering various tools and community features.
Scholar Rock Holding Corp. Actuals & Estimates (SWB:2QK)
This article provides an overview of Scholar Rock Holding Corp. (SWB:2QK) including its stock ticker, analyst forecast, historical high and low prices, and financial data. It details the company's past earnings and revenue, upcoming earnings report date, and confirms it does not pay dividends.
Scholar Rock Holding Corp. Actuals & Estimates (BOATS:SRRK)
This article provides financial actuals and estimates for Scholar Rock Holding Corporation (SRRK) traded on the BOATS exchange. It details analyst price targets ranging from $48.00 to $70.00, past earnings reports, and future earnings estimates. Additionally, it covers the company's revenue, net income, employee count, and stock price dynamics.
2QK Forecast — Price Target — Prediction for 2027
This article provides a forecast for Scholar Rock Holding Corp. (2QK) stock, including analyst price targets, ratings, and financial performance. It covers historical stock prices, upcoming earnings dates, recent financial results, and details about the company's revenue, net income, and employee count. The article also includes a disclaimer that the information is not investment advice.
Scholar Rock Holding Corp stock hits 52-week high at 52.21 USD
Scholar Rock Holding Corp (SRRK) has reached a new 52-week high of $52.19, with shares trading around $52.11, marking a 53.5% surge over the past year. This achievement is backed by analyst optimism, with four analysts revising earnings estimates upward, despite its InvestingPro analysis suggesting it's overvalued relative to its Fair Value. The company is actively pursuing product development and regulatory processes for apitegromab, a treatment for spinal muscular atrophy, with a PDUFA date set for September 30, 2026.
Scholar Rock Holding Corp stock hits 52-week high at 52.21 USD
Scholar Rock Holding Corp (SRRK) has reached a new 52-week high of $52.19, with shares currently trading at $52.11, marking a 53.5% surge over the past year. Despite a slight miss on Q1 2026 EPS, analyst optimism remains strong, with four analysts revising earnings estimates upward. The company is actively pursuing regulatory approval for apitegromab, a treatment for spinal muscular atrophy, with a PDUFA date set for September 30, 2026.
Scholar Rock Holding eyes key EMA decision, shares trade higher on NASDAQ
Scholar Rock Holding is nearing a key EMA review decision for its lead SMA therapy, apitegromab, which is scheduled for June 30, 2026. This comes ahead of a US FDA PDUFA date on September 30, 2026, after a recent resubmission of its biologics license application. The company's shares are trading near recent highs on NASDAQ, driven by these regulatory milestones and strong analyst interest, despite a Q1 2026 earnings miss.
Scholar Rock Holding (SRRK) Is Up 7.1% After Apitegromab BLA Resubmission And Dual Supply Strategy - Has The Bull Case Changed?
Scholar Rock Holding (SRRK) recently resubmitted its biologics license application for apitegromab, which now includes two fill-finish facilities and has a PDUFA date of September 30, 2026. This dual supply strategy aims to reduce operational risk for the spinal muscular atrophy therapy. While the company faces significant cash burn ($105.51 million in Q1 2026) and a clear regulatory timeline, investors should consider the risks of real-world outcomes and potential manufacturing setbacks.
Scholar Rock brings new apitegromab data to two rare muscle-disease meetings
Scholar Rock (NASDAQ: SRRK) announced it will present new clinical data and research updates related to its neuromuscular portfolio, including the Phase 3 SAPPHIRE and Phase 2 FORGE studies, at two upcoming meetings. The data will be shared at the 2026 Annual Cure SMA Research and Clinical Care Meeting and the 2026 International Research Congress on FSHD. Apitegromab, an investigational antibody inhibiting myostatin activation, is being developed for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD).
Scholar Rock Holding Corp (SRRK) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Scholar Rock Holding Corp (SRRK), detailing its current earnings forecast score, analyst ratings, and price targets. It highlights that the company's stock has an average price target of $47.50, with a majority of analysts recommending a "Buy." The report also includes expected revenue for the next quarter and past/future EPS performance.
Scholar Rock Holding Corp (SRRK) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Scholar Rock Holding Corp's (SRRK) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and lists no historical stock split data. The current stock price, market cap, and trading hours are also mentioned.
Cantor Fitzgerald reiterates Overweight on Scholar Rock stock
Cantor Fitzgerald maintained an Overweight rating on Scholar Rock Holding Corp. after meeting with management, citing the company's strong past year performance and updated regulatory pathway for apitegromab. The drug, a latent myostatin inhibitor for spinal muscular atrophy, has a PDUFA date of September 30, 2026, with the regulatory concerns regarding manufacturing having been addressed by including a second fill-finish facility. The positive outlook is supported by InvestingPro data showing analyst earnings revisions.
Armistice Capital LLC Takes Position in Scholar Rock Holding Corporation $SRRK
Armistice Capital LLC has initiated a new position in Scholar Rock Holding Corporation (NASDAQ: SRRK), purchasing 200,000 shares valued at approximately $8.81 million. This move represents 0.20% ownership for Armistice Capital. The company continues to receive positive sentiment from Wall Street, with a consensus "Buy" rating and an average price target of $56, despite reporting a slightly larger-than-expected quarterly loss.
Scholar Rock Holding Corp (SRRK) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Scholar Rock Holding Corp (SRRK), listing major shareholders such as Fidelity Management & Research Company LLC and Invus Public Equities Advisors, LLC, along with their respective proportions. It also presents a breakdown of shareholder types, including investment advisors and hedge funds. Furthermore, the report provides institutional shareholding data over several quarters and lists related ETFs that hold SRRK shares.
Scholar Rock Holding Corp (SRRK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Scholar Rock Holding Corp (SRRK), focusing on business segments and regional revenue contributions. However, it states that relevant data for FY2025 and FY2024 have not yet been disclosed by the company. The only specific data point mentioned is 0.00% revenue proportion from the United States.
Scholar Rock Holding Stock (US8063231019): Quarterly earnings and pipeline put biotech in focus
Scholar Rock Holding (SRRK) is gaining investor attention following its latest quarterly earnings report, which highlighted strong cash reserves and advancements in its clinical pipeline for spinal muscular atrophy and oncology. As a small-cap biotech, the company's financial results and pipeline milestones are crucial for assessing its ability to fund its strategy without seeking additional capital. The focus remains on strategic R&D spending, upcoming data readouts, and potential market partnerships to drive future growth and valuation.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock announced it granted inducement equity awards covering 134,345 shares to eleven new employees under Nasdaq Listing Rule 5635(c)(4). These awards include stock options and restricted stock units, subject to vesting schedules and the company's 2022 Inducement Equity Plan. The grants are a material inducement for individuals to join Scholar Rock and are consistent with Nasdaq rules for new hires.
Scholar Rock hands new hires 134,345 shares in stock awards
Scholar Rock (NASDAQ: SRRK) announced granting 134,345 inducement equity awards to eleven new employees as hiring incentives. These awards include stock options to purchase 50,936 shares and restricted stock units covering 83,409 shares, issued under Nasdaq Listing Rule 5635(c)(4) and the company's 2022 Inducement Equity Plan. The stock options have an exercise price of $43.80 and will vest over four years, while restricted stock units will vest in four equal annual installments, all contingent on continued employment.
Transcript : Scholar Rock Holding Corporation Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 10
Scholar Rock Holding Corporation presented at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 10:00 AM EDT. The transcript indicates a presentation by David Hallal from Scholar Rock. The full article content is reserved for subscribers.
Scholar Rock Holding Corp (SRRK) Stock Price & 30 Year Financial Data
This page provides a detailed look at Scholar Rock Holding Corp (SRRK)'s financial data over 30 years, offering key metrics such as market cap, enterprise value, PE ratio, PB ratio, and GF Score. It also includes growth rates for revenue, EPS, EBIT, EBITDA, free cash flow, dividends, book value, and price performance. The content is presented by GuruFocus, a financial analysis platform.
Scholar Rock (SRRK) director Michael Gilman awarded RSUs and stock options
Scholar Rock Holding Corp. director Michael Gilman has been awarded 6,839 Restricted Stock Units (RSUs) and options to purchase 4,310 shares of common stock at an exercise price of $45.33 per share. These awards will vest based on continued service to the company, with the RSUs vesting by June 15, 2027, or the next Annual Meeting, and the options vesting one year post-grant or at the next Annual Meeting and expiring in 2036. Following these transactions, Gilman's direct holdings include 62,055 common shares (comprising 55,216 shares and 6,839 RSUs) and 4,310 stock options.
Scholar Rock (SRRK) director awarded RSUs and 4,310 stock options
Jeffrey S. Flier, a director at Scholar Rock Holding Corp (SRRK), was granted 6,839 Restricted Stock Units (RSUs) and 4,310 stock options with an exercise price of $45.33 per share. These equity awards are part of his compensation, designed to align his interests with the company's long-term performance and continued service. The RSUs and options include specific vesting schedules tied to continued service or the company's next Annual Meeting.
Scholar Rock (SRRK) director receives RSU and stock option grants
Scholar Rock Holding Corp director Richard Brudnick received compensation in the form of 6,839 restricted stock units (RSUs) and stock options for 4,310 shares. These grants, reported on a Form 4 filing, are not open-market purchases and are subject to vesting schedules contingent on his continued service to the company. Following these grants, Brudnick's total common-share interests in Scholar Rock amount to 21,896, including both common stock and RSUs.
Scholar Rock (NASDAQ: SRRK) director receives new RSU and stock option grants
Scholar Rock Holding Corp director Kristina Burow recently received new equity awards, including 6,839 restricted stock units (RSUs) and an option grant for 4,310 shares of common stock with an exercise price of $45.33. These awards are part of her compensation and will vest subject to continued service. While Burow's direct holdings have increased to 110,871 common shares plus RSUs, she disclaims beneficial ownership of 2,345,711 common shares held indirectly by ARCH Venture Fund VIII, L.P.
Scholar Rock (SRRK) director Joshua Reed receives RSU and option grants
Scholar Rock Holding Corp (SRRK) director Joshua Reed received equity compensation, including 6,839 Restricted Stock Units (RSUs) and options for 4,310 shares at an exercise price of $45.33 per share. These grants are part of his routine compensation package, with vesting conditional on continued service. Following these transactions, Reed's total holdings include 22,571 common shares and RSUs, plus the 4,310 stock options.
Scholar Rock (NASDAQ: SRRK) director gets RSUs and 4,310 stock options
Scholar Rock Holding Corp director Srinivas Akkaraju received new equity awards, including 6,839 restricted stock units (RSUs) and options for 4,310 shares of common stock. These grants increase his direct common stock holdings to 27,971 shares after including both existing shares and the new RSUs. The RSUs and options have specific vesting schedules tied to continued service, and Akkaraju also has significant indirect holdings through affiliated investment funds.
Scholar Rock (SRRK) holders approve directors, auditor and executive pay
Scholar Rock Holding Corporation shareholders recently approved the election of four Class II directors for three-year terms, ratified Deloitte & Touche LLP as the independent auditor for fiscal year 2026, and gave non-binding advisory approval for the compensation of their named executive officers. These decisions confirm continued shareholder support for the company's board composition, auditor choice, and executive pay structure. The results were reported in an 8-K filing following the annual stockholder meeting held on June 4, 2026.
SRRK - Scholar Rock Holding Corp Stock Price and Quote
This page provides a detailed overview of Scholar Rock Holding Corp (SRRK) stock, including its latest financial data, key performance indicators, analyst ratings, and recent news. It also lists insider trading activities, showing transactions by various officers and directors. The company is a biopharmaceutical firm focused on developing medicines for serious diseases.
Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Scholar Rock (NASDAQ: SRRK) announced that its management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, on Tuesday, June 9, 2026, at 10:00 a.m. ET. A live webcast of the event will be available on the Investors section of Scholar Rock's website, with a replay accessible for about 90 days. The company is a late-stage biopharmaceutical firm focused on developing treatments for spinal muscular atrophy (SMA) and other neuromuscular diseases.
Spinal muscular atrophy biopharma to speak at Goldman Sachs healthcare event
Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company focused on spinal muscular atrophy (SMA) and other neuromuscular diseases, announced its management will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The presentation will be webcast live and a replay will be available for approximately 90 days on the company's investor relations website. Scholar Rock is recognized for its leadership in myostatin biology to advance musculoskeletal health.
Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Scholar Rock (NASDAQ: SRRK) announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 10:00 a.m. ET. The biopharmaceutical company, focused on treating spinal muscular atrophy (SMA) and other neuromuscular diseases, will make a live webcast of the event available on its Investors section. A replay will be accessible for approximately 90 days following the presentation.
Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Scholar Rock announced that its management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL. The presentation is scheduled for Tuesday, June 9, 2026, at 10:00 a.m. ET. A live webcast and subsequent replay will be available on the Investors section of Scholar Rock’s website.
Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference
Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company focused on neuromuscular diseases, announced that its management will present at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 11:40 a.m. ET. A live webcast and replay of the presentation will be accessible via the Investors section of the company's website. Scholar Rock specializes in developing treatments for spinal muscular atrophy (SMA) and other rare diseases through its myostatin biology platform.
Biotech Scholar Rock to webcast Jefferies healthcare talk June 3
Scholar Rock (NASDAQ: SRRK) announced that its management will participate in the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 11:40 a.m. ET. The company, which specializes in therapies for spinal muscular atrophy and other neuromuscular diseases, will provide a live webcast of the presentation. A replay will also be available on Scholar Rock's investor relations website for approximately 90 days following the event.
Charles Schwab Investment Management Inc. Acquires 25,060 Shares of Scholar Rock Holding Corporation $SRRK
Charles Schwab Investment Management Inc. increased its stake in Scholar Rock Holding Corporation by 3.7% in the fourth quarter, acquiring an additional 25,060 shares, bringing its total holdings to 702,095 shares valued at $30.9 million. Wall Street analysts maintain a generally bullish outlook on SRRK, with a consensus "Buy" rating and an average target price of $56.00. The article also notes recent insider sales by the CEO and CFO, which were attributed to tax withholding obligations related to equity awards.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock announced new inducement equity awards for six newly hired employees, totaling 38,481 shares of common stock. These grants, comprising stock options and restricted stock units, are issued under the company's 2022 Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The awards are designed to attract new talent, with specific vesting schedules for both the stock options and restricted stock units.
Redmile Group owns 7.6% of Scholar Rock (SRRK) via funds and affiliates
Redmile Group, through its various funds and affiliates, reported a 7.6% beneficial ownership stake in Scholar Rock Holding Corporation (SRRK), totaling 9,066,621 shares of common stock. This ownership is based on 119,103,774 shares outstanding as of March 31, 2026. The filing, an amendment to a prior Schedule 13G/A, indicates shared voting and dispositive power, with Redmile and Jeremy C. Green disclaiming beneficial ownership except for any pecuniary interest.
Earnings call transcript: Scholar Rock Q1 2026 sees EPS miss, stock rises
Scholar Rock (SRRK) reported a Q1 2026 EPS of -$0.83, missing the -$0.80 forecast, yet its stock rose 2.72% in pre-market trading due to positive market reaction to strategic updates. The FDA has accepted a Biologics License Application for apitegromab with a PDUFA date of September 30, 2026, and the company maintains a strong cash position of $480 million to support its commercial launch readiness in the U.S. and Europe. Scholar Rock is also advancing its anti-myostatin pipeline with other programs for SMA and FSHD, aiming to address significant unmet medical needs.
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q1 2026 Earnings Call Transcript
Scholar Rock Holding Corporation announced that the FDA accepted its Biologics License Application (BLA) for apitegromab for spinal muscular atrophy (SMA), setting a PDUFA action date of September 30, 2026. The BLA includes two fill-finish facilities, providing independent paths to approval. The company is actively preparing for commercial launch in the U.S. and Europe, anticipating approval and launch of the muscle-targeted therapy for SMA patients.
Earnings call transcript: Scholar Rock Q1 2026 sees EPS miss, stock rises
Scholar Rock (SRRK) reported a Q1 2026 EPS of -$0.83, missing analyst forecasts, yet its stock rose 2.72% in pre-market trading, driven by the FDA's acceptance of the Biologics License Application for apitegromab with a PDUFA date of September 30, 2026. The company discussed its strong cash position of $480 million and significant progress in commercial readiness for apitegromab in both U.S. and European markets. Management expressed confidence in a successful launch of its SMA treatment, emphasizing strategic advancements despite the EPS miss.
TradingKey
This page provides an overview of Scholar Rock Holding Corp (SRRK) on the TradingKey platform, including its market data, such as its current price of $48.360 and a slight decrease of 0.06%. The content highlights the stock's market capitalization of $5.76 billion and offers sections for financials, discussions, and analysis, but the specific details of these sections are not provided. The page also mentions tools like stock screener and economic calendar and has disclaimers about delayed data and investment risks.
Number of shareholders of Scholar Rock Holding Corp. – FWB:2QK
The article provides a financial overview page for Scholar Rock Holding Corp. (FWB:2QK) on TradingView, specifically focusing on the number of shareholders. It includes market data, reference data, and links to SEC filings, but does not present the shareholder number itself, instead offering a placeholder for "Period," "Value," "Change," and "Change %".
Is Scholar Rock Holding (SRRK) Offering Value After Its Strong Multi Year Share Price Gains
Scholar Rock Holding (SRRK) has experienced mixed recent returns but has seen significant multi-year gains. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 70.5%, with a projected intrinsic value of $157.25 per share. However, its Price-to-Book (P/B) ratio of 20.08x indicates it may be overvalued when compared to the biotech industry average and its own "Fair Ratio" framework.
Scholar Rock (NASDAQ:SRRK) Issues Quarterly Earnings Results
Scholar Rock (NASDAQ:SRRK) reported quarterly earnings of ($0.83) per share, slightly missing the consensus estimate and worsening from the previous year. Despite the earnings miss, the company announced that the FDA accepted its Biologics License Application (BLA) for apitegromab to treat spinal muscular atrophy, setting a PDUFA action date of September 30, 2026. The stock saw a 4.2% increase, and analysts maintain a "Buy" rating with a consensus price target of $56.00, while insider selling was noted to cover tax obligations.
